Beximco Pharmaceuticals (LON:BXP) Sets New 52-Week High - Still a Buy?

Key Points

• Beximco Pharmaceuticals has reached a new 52-week high, trading at GBX 41 ($0.55), following a increase of 3.8% in stock price.
• The company has a market capitalization of £27.95 billion, a PE ratio of 4.40, and a debt-to-equity ratio of 12.47.
• Beximco Pharmaceuticals, established in 1976, is a leading manufacturer and exporter of medicines based in Bangladesh, starting with imports and transitioning to manufacturing under licensing agreements.

Shares of Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as GBX 41 ($0.54) and last traded at GBX 41 ($0.54), with a volume of 33469 shares traded. The stock had previously closed at GBX 39.50 ($0.52).

Beximco Pharmaceuticals Price Performance

The company has a market cap of £26.59 billion, a price-to-earnings ratio of 4.18 and a beta of 0.61. The company has a current ratio of 2.13, a quick ratio of 0.37 and a debt-to-equity ratio of 12.47. The company's 50 day moving average price is GBX 37.74 and its 200 day moving average price is GBX 37.83.

About Beximco Pharmaceuticals

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.